text: Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both AChE and BuChE, << rivastigmine >>, indicates potential therapeutic benefits of inhibiting both [[ AChE ]] and BuChE in AD and related dementias.